Resolution of Inflammation in Asthma

Clinics in Chest Medicine

Volumn 33, Issue 3, 2012, Pages 559-570

  Levy, Bruce D ^a   Vachier, Isabelle ^b   Serhan, Charles N ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

Asthma; Inflammation; Lipoxins; Mediators; Resolution

Indexed keywords

FORMYLPEPTIDE RECEPTOR LIKE 1; LIPOXIN A; OMEGA 3 FATTY ACID; POLYUNSATURATED FATTY ACID; PROTECTIN D1; RECEPTOR PROTEIN; RESOLVIN E1; RESOLVIN E1 RECEPTOR; UNCLASSIFIED DRUG;

ASTHMA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FATTY ACID ANALYSIS; FATTY ACID METABOLISM; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ACUTE DISEASE; ASTHMA; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS;

EID: 84865551885     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2012.06.006     Document Type: Review

References (120)

1. Fanta C.H. Asthma. N Engl J Med 2009, 360:1002.
2. Bousquet J., Jeffery P.K., Busse W.W., et al. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000, 161:1720.
3. Busse W.W., Lemanske R.F. Asthma. N Engl J Med 2001, 344:350.
4. Nathan C., Ding A. Nonresolving inflammation. Cell 2010, 140:871.
5. Serhan C.N. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 2007, 25:101.
6. Levy B.D., Clish C.B., Schmidt B., et al. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2001, 2:612.
7. Burr G.O., Burr M.M. A new deficiency disease produced by the rigid exclusion of fat from the diet. J Biol Chem 1929, 82:345.
8. Serhan C.N. The resolution of inflammation: the devil in the flask and in the details. FASEB J 2011, 25:1441.
9. Serhan C.N., Clish C.B., Brannon J., et al. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 2000, 192:1197.
10. Serhan C.N., Hong S., Gronert K., et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002, 196:1025.
11. Savill J., Apoptosis Phagocytic docking without shocking. Nature 1998, 392:442.
12. Savill J.S., Wyllie A.H., Henson J.E., et al. Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Invest 1989, 83:865.
13. Fadok V.A., Bratton D.L., Konowal A., et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998, 101:890.
14. Freire-de-Lima C.G., Xiao Y.Q., Gardai S.J., et al. Apoptotic cells, through transforming growth factor-beta, coordinately induce anti-inflammatory and suppress pro-inflammatory eicosanoid and NO synthesis in murine macrophages. J Biol Chem 2006, 281:38376.
15. Savill J., Fadok V. Corpse clearance defines the meaning of cell death. Nature 2000, 407:784.
16. Gilroy D.W., Lawrence T., Perretti M., et al. Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov 2004, 3:401.
17. Bannenberg G.L., Chiang N., Ariel A., et al. Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol 2005, 174:4345. [Erratum appears in J Immunol. 2005 May 1;174(9):5884].
18. Serhan C.N., Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol 2005, 6:1191.
19. Majno G. Cells, tissues and disease: principles of general pathology 1996, Blackwell, Cambridge (MA).
20. Woodruff P.G., Boushey H.A., Dolganov G.M., et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci U S A 2007, 104:15858.
21. Woodruff P.G., Modrek B., Choy D.F., et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009, 180:388.
22. Samuelsson B. From studies of biochemical mechanisms to novel biological mediators: prostaglandin endoperoxides, thromboxanes and leukotrienes. Les prix Nobel: Nobel prizes, presentations, biographies and lectures 1982, 153. Almqvist & Wiksell, Stockholm (Sweden).
23. Wills-Karp M., Luyimbazi J., Xu X., et al. Interleukin-13: central mediator of allergic asthma. Science 1998, 282:2258.
24. Zhen G., Park S.W., Nguyenvu L.T., et al. IL-13 and epidermal growth factor receptor have critical but distinct roles in epithelial cell mucin production. Am J Respir Cell Mol Biol 2007, 36:244.
25. Moore W.C., Bleecker E.R., Curran-Everett D., et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007, 119:405.
26. Serhan C.N., Brain S.D., Buckley C.D., et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J 2007, 21:325.
27. Bandeira-Melo C., Serra M.F., Diaz B.L., et al. Cyclooxygenase-2-derived prostaglandin E2 and lipoxin A4 accelerate resolution of allergic edema in Angiostrongylus costaricensis-infected rats: relationship with concurrent eosinophilia. J Immunol 2000, 164:1029.
28. Maddox J.F., Serhan C.N. Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction. J Exp Med 1996, 183:137.
29. Godson C., Mitchell S., Harvey K., et al. Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol 2000, 164:1663.
30. Ariel A., Fredman G., Sun Y.P., et al. Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat Immunol 2006, 7:1209.
31. Lawrence D.W., Bruyninckx W.J., Louis N.A., et al. Antiadhesive role of apical decay-accelerating factor (CD55) in human neutrophil transmigration across mucosal epithelia. J Exp Med 2003, 198:999.
32. Campbell E.L., Louis N.A., Tomassetti S.E., et al. Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. FASEB J 2007, 21:3162.
33. Canny G., Levy O., Furuta G.T., et al. Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci U S A 2002, 99:3902.
34. Souza D.G., Fagundes C.T., Amaral F.A., et al. The required role of endogenously produced lipoxin A4 and annexin-1 for the production of IL-10 and inflammatory hyporesponsiveness in mice. J Immunol 2007, 179:8533.
35. Fukunaga K., Kohli P., Bonnans C., et al. Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury. J Immunol 2005, 174:5033.
36. Gilroy D.W., Colville-Nash P.R., Willis D., et al. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999, 5:698. [see comments].
37. Schwab J.M., Chiang N., Arita M., et al. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007, 447:869.
38. Samuelsson B., Dahlen S.E., Lindgren J.A., et al. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987, 237:1171.
39. Bazan N.G. Synaptic lipid signaling: significance of polyunsaturated fatty acids and platelet-activating factor. J Lipid Res 2003, 44:2221.
40. Freedman S.D., Blanco P.G., Zaman M.M., et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 2004, 350:560.
41. Albert C.M., Campos H., Stampfer M.J., et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 2002, 346:1113.
42. Gong J., Rosner B., Rees D.G., et al. Plasma docosahexaenoic acid levels in various genetic forms of retinitis pigmentosa. Invest Ophthalmol Vis Sci 1992, 33:2596.
43. Kew S., Mesa M.D., Tricon S., et al. Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on immune cell composition and function in healthy humans. Am J Clin Nutr 2004, 79:674.
44. Miles E.A., Noakes P.S., Kremmyda L.S., et al. The Salmon in Pregnancy Study: study design, subject characteristics, maternal fish and marine n-3 fatty acid intake, and marine n-3 fatty acid status in maternal and umbilical cord blood. Am J Clin Nutr 2011, 94:1986S.
45. Newcomer L.M., King I.B., Wicklund K.G., et al. The association of fatty acids with prostate cancer risk. Prostate 2001, 47:262.
46. Wakai K., Ito Y., Kojima M., et al. Intake frequency of fish and serum levels of long-chain n-3 fatty acids: a cross-sectional study within the Japan Collaborative Cohort Study. J Epidemiol 2005, 15:211.
47. Serhan C.N., Fredman G., Yang R., et al. Novel proresolving aspirin-triggered DHA pathway. Chem Biol 2011, 18:976.
48. Serhan C.N., Yang R., Martinod K., et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 2009, 206:15.
49. Yang R., Fredman G., Krishnamoorthy S., et al. Decoding functional metabolomics with docosahexaenoyl ethanolamide (DHEA) identifies novel bioactive signals. J Biol Chem 2011, 286:31532.
50. Meini S., Evangelista S., Geppetti P., et al. Pharmacologic and neurochemical evidence for the activation of capsaicin-sensitive sensory nerves by lipoxin A4 in guinea pig bronchus. Am Rev Respir Dis 1992, 146:930.
51. Svensson C.I., Zattoni M., Serhan C.N. Lipoxins and aspirin-triggered lipoxin inhibit inflammatory pain processing. J Exp Med 2007, 204:245.
52. Hunter J.A., Finkbeiner W.E., Nadel J.A., et al. Predominant generation of 15-lipoxygenase metabolites of arachidonic acid by epithelial cells from human trachea. Proc Natl Acad Sci U S A 1985, 82:4633.
53. Levy B.D., Romano M., Chapman H.A., et al. Human alveolar macrophages have 15-lipoxygenase and generate 15(S)-hydroxy-5,8,11-cis-13-trans-eicosatetraenoic acid and lipoxins. J Clin Invest 1993, 92:1572.
54. Serhan C.N., Hirsch U., Palmblad J., et al. Formation of lipoxin A by granulocytes from eosinophilic donors. FEBS Lett 1987, 217:242.
55. Shannon V.R., Chanez P., Bousquet J., et al. Histochemical evidence for induction of arachidonate 15-lipoxygenase in airway disease. Am Rev Respir Dis 1993, 147:1024.
56. Levy B.D., De Sanctis G.T., Devchand P.R., et al. Multi-pronged inhibition of airway hyperresponsiveness and inflammation by lipoxin A(4). Nat Med 2002, 8:1018. [see comment].
57. Claria J., Serhan C.N. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci U S A 1995, 92:9475.
58. Claria J., Lee M.H., Serhan C.N. Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation. Mol Med 1996, 2:583.
59. Birnbaum Y., Ye Y., Lin Y., et al. Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat. Circulation 2006, 114:929.
60. Planaguma A., Pfeffer M.A., Rubin G., et al. Lovastatin decreases acute mucosal inflammation via 15-epi-lipoxin A4. Mucosal Immunol 2010, 3:270.
61. Serhan C.N., Fiore S., Brezinski D.A., et al. Lipoxin A4 metabolism by differentiated HL-60 cells and human monocytes: conversion to novel 15-oxo and dihydro products. Biochemistry 1993, 32:6313.
62. Serhan C.N., Maddox J.F., Petasis N.A., et al. Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 1995, 34:14609.
63. Spite M., Serhan C.N. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res 2010, 107:1170.
64. Chiang N., Serhan C.N., Dahlen S.E., et al. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev 2006, 58:463.
65. Chiang N., Fierro I.M., Gronert K., et al. Activation of lipoxin A(4) receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation. J Exp Med 2000, 191:1197.
66. Hirai H., Tanaka K., Yoshie O., et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001, 193:255.
67. Serhan C.N., Fiore S., Levy B.D. Cell-cell interactions in lipoxin generation and characterization of lipoxin A4 receptors. Ann N Y Acad Sci 1994, 744:166.
68. Arita M., Bianchini F., Aliberti J., et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 2005, 201:713.
69. Levy B.D., Fokin V.V., Clark J.M., et al. Polyisoprenyl phosphate (PIPP) signaling regulates phospholipase D activity: a 'stop' signaling switch for aspirin-triggered lipoxin A4. FASEB J 1999, 13:903.
70. Ohira T., Bannenberg G., Arita M., et al. A stable aspirin-triggered lipoxin A4 analog blocks phosphorylation of leukocyte-specific protein 1 in human neutrophils. J Immunol 2004, 173:2091.
71. Gronert K., Gewirtz A., Madara J.L., et al. Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release. J Exp Med 1998, 187:1285.
72. Simiele F., Recchiuti A., Mattoscio D., et al. Transcriptional regulation of the human FPR2/ALX gene: evidence of a heritable genetic variant that impairs promoter activity. FASEB J 2012, 26(3):1323-1333.
73. Devchand P.R., Arita M., Hong S., et al. Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense. FASEB J 2003, 17:652. [Erratum appears in FASEB J. 2003 Jun;17(9):4].
74. Schaldach C.M., Riby J., Bjeldanes L.F. Lipoxin A4: a new class of ligand for the Ah receptor. Biochemistry 1999, 38:7594.
75. Badr K.F., DeBoer D.K., Schwartzberg M., et al. Lipoxin A4 antagonizes cellular and in vivo actions of leukotriene D4 in rat glomerular mesangial cells: evidence for competition at a common receptor. Proc Natl Acad Sci U S A 1989, 86:3438.
76. Gronert K., Martinsson-Niskanen T., Ravasi S., et al. Selectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4) receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses. Am J Pathol 2001, 158:3.
77. Aliberti J., Hieny S., Reis e Sousa C., et al. Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity. Nat Immunol 2002, 3:76.
78. Lee T.H., Crea A.E., Gant V., et al. Identification of lipoxin A4 and its relationship to the sulfidopeptide leukotrienes C4, D4, and E4 in the bronchoalveolar lavage fluids obtained from patients with selected pulmonary diseases. Am Rev Respir Dis 1990, 141:1453.
79. Planaguma A., Kazani S., Marigowda G., et al. Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. Am J Respir Crit Care Med 2008, 178:574.
80. Vachier I., Bonnans C., Chavis C., et al. Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound. J Allergy Clin Immunol 2005, 115:55.
81. Dahlen S.E., Franzen L., Raud J., et al. Actions of lipoxin A4 and related compounds in smooth muscle preparations and on the microcirculation in vivo. Adv Exp Med Biol 1988, 229:107.
82. Christie P.E., Spur B.W., Lee T.H. The effects of lipoxin A4 on airway responses in asthmatic subjects. Am Rev Respir Dis 1992, 145:1281.
83. Sanak M., Levy B.D., Clish C.B., et al. Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur Respir J 2000, 16:44.
84. Levy B.D., Bonnans C., Silverman E.S., et al. Diminished lipoxin biosynthesis in severe asthma. Am J Respir Crit Care Med 2005, 172:824.
85. Celik G.E., Erkekol F.O., Misirligil Z., et al. Lipoxin A4 levels in asthma: relation with disease severity and aspirin sensitivity. Clin Exp Allergy 2007, 37:1494.
86. Tahan F., Saraymen R., Gumus H. The role of lipoxin A4 in exercise-induced bronchoconstriction in asthma. J Asthma 2008, 45:161.
87. Karp C.L., Flick L.M., Park K.W., et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol 2004, 5:388.
88. Kowal-Bielecka O., Kowal K., Distler O., et al. Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: an imbalance between proinflammatory and antiinflammatory lipid mediators. Arthritis Rheum 2005, 52:3783.
89. Schwartz J., Weiss S.T. The relationship of dietary fish intake to level of pulmonary function in the first National Health and Nutrition Survey (NHANES I). Eur Respir J 1994, 7:1821.
90. Connor K.M., SanGiovanni J.P., Lofqvist C., et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 2007, 13:868.
91. Hudert C.A., Weylandt K.H., Lu Y., et al. Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci U S A 2006, 103:11276.
92. Bilal S., Haworth O., Wu L., et al. Fat-1 transgenic mice with elevated omega-3 fatty acids are protected from allergic airway responses. Biochim Biophys Acta 2011, 1812:1164.
93. Arita M., Ohira T., Sun Y.P., et al. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol 2007, 178:3912.
94. Cash J.L., Hart R., Russ A., et al. Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J Exp Med 2008, 205:767.
95. Samson M., Edinger A.L., Stordeur P., et al. ChemR23, a putative chemoattractant receptor, is expressed in monocyte-derived dendritic cells and macrophages and is a coreceptor for SIV and some primary HIV-1 strains. Eur J Immunol 1998, 28:1689.
96. Wittamer V., Franssen J.D., Vulcano M., et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003, 198:977.
97. Yokomizo T., Izumi T., Chang K., et al. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 1997, 387:620.
98. Aoki H., Hisada T., Ishizuka T., et al. Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma. Biochem Biophys Res Commun 2008, 367:509.
99. Haworth O., Cernadas M., Levy B.D. NK cells are effectors for resolvin E1 in the timely resolution of allergic airway inflammation. J Immunol 2011, 186:6129.
100. Haworth O., Cernadas M., Yang R., et al. Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol 2008, 9:873.
101. Serhan C.N., Gotlinger K., Hong S., et al. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J Immunol 2006, 176:1848.
102. Bazan N.G. Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease. J Lipid Res 2009, 50:S400.
103. Serhan C.N., Chiang N., Van Dyke T.E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008, 8:349.
104. Marcheselli V.L., Mukherjee P.K., Arita M., et al. Neuroprotectin D1/protectin D1 stereoselective and specific binding with human retinal pigment epithelial cells and neutrophils. Prostaglandins Leukot Essent Fatty Acids 2010, 82:27.
105. Kasuga K., Yang R., Porter T.F., et al. Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution. J Immunol 2008, 181:8677.
106. Levy B.D., Kohli P., Gotlinger K., et al. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol 2007, 178:496.
107. Bandeira-Melo C., Bozza P.T., Diaz B.L., et al. Cutting edge: lipoxin (LX) A4 and aspirin-triggered 15-epi-LXA4 block allergen-induced eosinophil trafficking. J Immunol 2000, 164:2267.
108. Ariel A., Chiang N., Arita M., et al. Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-alpha secretion from human T cells. J Immunol 2003, 170:6266.
109. Colgan S.P., Serhan C.N., Parkos C.A., et al. Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers. J Clin Invest 1993, 92:75.
110. Papayianni A., Serhan C.N., Brady H.R. Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. J Immunol 1996, 156:2264.
111. Soyombo O., Spur B.W., Lee T.H. Effects of lipoxin A4 on chemotaxis and degranulation of human eosinophils stimulated by platelet-activating factor and N-formyl-L-methionyl-L-leucyl-L-phenylalanine. Allergy 1994, 49:230.
112. Ramstedt U., Serhan C.N., Nicolaou K.C., et al. Lipoxin A-induced inhibition of human natural killer cell cytotoxicity: studies on stereospecificity of inhibition and mode of action. J Immunol 1987, 138:266.
113. Bonnans C., Vachier I., Chavis C., et al. Lipoxins are potential endogenous antiinflammatory mediators in asthma. Am J Respir Crit Care Med 2002, 165:1531.
114. Parameswaran K., Radford K., Fanat A., et al. Modulation of human airway smooth muscle migration by lipid mediators and Th-2 cytokines. Am J Respir Cell Mol Biol 2007, 37:240.
115. Brezinski M.E., Gimbrone M.A., Nicolaou K.C., et al. Lipoxins stimulate prostacyclin generation by human endothelial cells. FEBS Lett 1989, 245:167.
116. Bonnans C., Fukunaga K., Levy M.A., et al. Lipoxin A(4) regulates bronchial epithelial cell responses to acid injury. Am J Pathol 2006, 168:1064.
117. 2+ increase in human bronchial epithelium. J Biol Chem 2003, 278:10879.
118. Ariel A., Li P.L., Wang W., et al. The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering. J Biol Chem 2005, 280:43079.
119. Bhavsar P.K., Levy B.D., Hew M.J., et al. Corticosteroid suppression of lipoxin A4 and leukotriene B4 from alveolar macrophages in severe asthma. Respir Res 2010, 11:71.
120. Wu S.H., Yin P.L., Zhang Y.M., et al. Reversed changes of lipoxin A4 and leukotrienes in children with asthma in different severity degree. Pediatr Pulmonol 2010, 45:333.